Effect of procaterol, a β2 selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness

Allergology International

Volumn 56, Issue 3, 2007, Pages 241-247

  Tashimo, Hiroyuki ^a   Yamashita, Naomi ^a,b   Ishida, Hirofumi ^a   Nagase, Hiroyuki ^a   Adachi, Tetsuya ^a   Nakano, Junichi ^a   Yamamura, Koichi ^a   Yano, Tomoko ^a   Yoshihara, Hisanao ^a   Ohta, Ken ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

Airway hyperresponsiveness; Allergic inflammation; Eosinophil; Murine model; 2 adrenergic receptor agonist

Indexed keywords

ACETYLCHOLINE; ALUMINUM POTASSIUM SULFATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; DEXAMETHASONE; MESSENGER RNA; OVALBUMIN; PROCATEROL;

AIRWAY RESISTANCE; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLOGY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SELECTIVITY; EOSINOPHIL COUNT; IMMUNIZATION; INHALATION; LUNG LAVAGE; LUNG VENTILATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION; RESPIRATORY TRACT INFLAMMATION; THICKNESS; TRACHEOSTOMY;

EID: 34548813852     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.O-06-456     Document Type: Article

References (49)

1. Romagnani S. Cytokines and chemoattractants in allergic inflammation. Mol. Immunol. 2002;38:881-885.
2. Schwartz RS. A new element in the mechanism of asthma. N. Engl. J. Med. 2002;346:857-858.
3. Makino S, Adachi M, Ago Y et al. Pharmacologic control of asthma. Int. Arch. Allergy Immunol. 2005;136 (Suppl 1):14-49.
4. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004;170:836-844.
5. Tsuchida T, Matsuse H, Machida I et al. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy Asthma Proc. 2005;26:287-291.
6. South M. Second line treatment for severe acute childhood asthma. Thorax 2003;58:284-285.
7. Helms PJ. Corticosteroid-sparing options in the treatment of childhood asthma. Drugs 2000;59 (Suppl 1):15-22.
8. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344:219-224.
9. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996;153:1481-1488.
10. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Brit. Med. J. 2000; 320:1368-1373.
11. Butchers PR, Vardey CJ, Johnson M. Salmeterol. A potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 1991;104:672-676.
12. Tachibana A, Kato M, Kimura H, Fujiu T, Suzuki M, Morikawa A. Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor- independent actions. Clin. Exp. Immunol. 2002;130:415-423.
13. Ezeamuzie CI, al-Hage M. Differential effects of salbutamol and salmeterol on human eosinophil responses. J. Pharmacol. Exp. Ther. 1998;284:25-31.
14. Hallsworth MP, Twort CH, Lee TH, Hirst SJ. beta (2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br. J. Pharmacol. 2001;132:729-741.
15. Yasui K, Kobayashi N, Yamazaki T et al. Differential Effects of Short-Acting beta (2)-Agonists on Human Granulocyte Functions. Int. Arch. Allergy Immunol. 2005;139:1-8.
16. Momose T, Okubo Y, Horie S et al. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int. Arch. Allergy Immunol. 1998;117:138-145.
17. Sears MR. Adverse effects of beta-agonists. J. Allergy Clin. Immunol. 2002;110:S322-328.
18. Kamachi A, Munakata M, Nasuhara Y et al. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 2001;56:19-24.
19. 2 receptor expression and function in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 1999;21:409-417.
20. 2-agonists and corticosteroids. Faseb J. 2001;15: 261-269.
21. Reid DW, Ward C, Wang N et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur. Respir. J. 2003;21:994-999.
22. 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 1999;160:1493-1499.
23. Di Lorenzo G, Morici G, Norrito F et al. Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Clin. Exp. Allergy 1995;25:951-956.
24. 2-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am. J. Respir. Cell Mol. Biol. 2000; 23:79-85.
25. 2-agonists and corticosteroids. Eur. Respir. J. 2002;19:182-191.
26. Pace E, Gagliardo R, Melis M et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J. Allergy Clin. Immunol. 2004;114:1216-1223.
27. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Brit. Med. J. 2003;327:891.
28. Currie GP, Lee DK, Haggart K et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am. J. Respir. Crit. Care Med. 2003;167:1232-1238.
29. Lindqvist A, Karjalainen EM, Laitinen LA et al. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J. Allergy Clin. Immunol. 2003;112: 23-28.
30. Levitt RC, Mitzner W. Expression of airway hyperreactivity to acetylcholine as a simple autosomal recessive trait in mice. Faseb. J. 1988;2:2605-2608.
31. Levitt RC, Mitzner W. Autosomal recessive inheritance of airway hyperreactivity to 5-hydroxytryptamine. J. Appl. Physiol. 1989;67:1125-1132.
32. Yamashita N, Tashimo H, Ishida H et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell. Immunol. 2002;219: 92-97.
33. Ohta K, Yamashita N, Tajima M et al. Diesel exhaust particulate induces airway hyperresponsiveness in a murine model: essential role of GM-CSF. J. Allergy Clin. Immunol. 1999;104:1024-1030.
34. Eldon MA, Battle MM, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA. Clinical pharmacokinetics and relative bioavailability of oral procaterol. Pharm. Res. 1993;10: 603-605.
35. Eldon MA, Blake DS, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA. Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharm. Drug Dispos. 1992;13:663-669.
36. Apter AJ. Clinical advances in adult asthma. J. Allergy Clin. Immunol. 2003;111:S780-784.
37. Sears MR, Rea HH, Beaglehole R et al. Asthma mortality in New Zealand: a two year national study. N. Z. Med. J. 1985;98:271-275.
38. 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994;11:259-283.
39. 2- adrenoceptor agonists in asthma management. Respir. Med. 2005;99:152-170.
40. Johnson M. The beta-adrenoceptor. Am. J. Respir. Crit. Care Med. 1998;158:S146-153.
41. Robison GA, Butcher RW, Sutherland EW. Adenyl cyclase as an adrenergic receptor. Ann. N. Y. Acad. Sci. 1967; 139:703-723.
42. Zidek Z. Adenosine-cyclic AMP pathways and cytokine expression. Eur. Cytokine Netw. 1999;10:319-328.
43. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J. Allergy Clin. Immunol. 2000;106:77-83.
44. Hallsworth MP, Giembycz MA, Barnes PJ, Lee TH. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br. J. Pharmacol. 1996;117:79-86.
45. Adachi T, Motojima S, Hirata A et al. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J. Allergy Clin. Immunol. 1996; 98:S207-215.
46. Ohta K, Yamashita N, Tajima M et al. In vivo effects of apoptosis in asthma examined by a murine model. Int. Arch. Allergy Immunol. 2001;124:259-261.
47. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J. Clin. Invest. 1997; 100:1677-1684.
48. Koyama S, Sato E, Masubuchi T et al. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur. Respir. J. 1999;14:767-775.
49. 2-agonist, attenuates eosinophils adhesion to endothelial cells. Allergol. Int. 2005;54:283-288.